Search - tctmd.com

Displaying 261 - 272 of 272

Sort: Relevancy | Date

News Daily News

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Jason Kahn

June 22, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

L.A. McKeown

June 06, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Daily News

Risk of Intracranial Hemorrhage, Mortality Lower with Dabigatran in A-fib Patients

L.A. McKeown

April 30, 2012

News Daily News

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

Caitlin E. Cox

April 26, 2012

News Daily News

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Caitlin E. Cox

April 26, 2012

News Daily News

Hope Renewed for Novel Anticoagulant Use in ACS

Caitlin E. Cox

October 05, 2011

News Daily News

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

Caitlin E. Cox

September 14, 2011

News Conference News

ESC Congress 2011: Drugs, Devices Work Together

Caitlin E. Cox

September 06, 2011

News Conference News

Novel Anticoagulants Showing Benefits in A-fib Subgroups

August 29, 2011

News Daily News

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Jason Kahn

July 25, 2011

Advertisement

RE-LY: El Dabigatran Acorta la Interrupción del Fármaco sin Aumentar los Episodios Hemorrágicos

Rivaroxaban May be Cost-Effective for A-fib Patients

El Rivaroxaban podría ser Rentable en Pacientes con Fibrilación Auricular

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Risk of Intracranial Hemorrhage, Mortality Lower with Dabigatran in A-fib Patients

ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients

ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular

Hope Renewed for Novel Anticoagulant Use in ACS

Rivaroxaban Continues Emergence of New Class of Anticoagulants for A-Fib

ESC Congress 2011: Drugs, Devices Work Together

Novel Anticoagulants Showing Benefits in A-fib Subgroups

Apixaban Increases Major Bleeding in High-Risk ACS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content